Understand the source comparison
Peptides for Gut Health: Dosage & Administration Comparison
BPC-157 200–500 mcg daily Subcutaneous injection or oral (enteric-coated) VEGF upregulation, tight junction protein expression, NOS pathway activation 7–14 days for barrier markers; 21+ days for mucosal healing Strongest evidence for structural repair; oral bi
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- 200–500 mcg daily
- Subcutaneous injection or oral (enteric-coated)
- VEGF upregulation, tight junction protein expression, NOS pathway activation
- 7–14 days for barrier markers; 21+ days for mucosal healing
- Strongest evidence for structural repair; oral bioavailability debated but subcutaneous route consistently effective
- KPV (Lys-Pro-Val)
- 500 mcg–2 mg daily
- Oral (targeted-release capsule)
- MC1R agonism, NF-κB inhibition, cytokine suppression
- 4–8 weeks for clinical remission in IBD models
- Only peptide with Phase 2 human data in ulcerative colitis; well-tolerated with minimal systemic absorption
- Thymalin
- 5–10 mg (2–3x/week)
- Subcutaneous or intramuscular injection
- Thymic peptide; enhances Treg output, modulates gut-associated lymphoid tissue (GALT)
- 14–21 days for immune marker changes; 30+ days for symptomatic improvement
- Indirect gut benefit via immune regulation; best combined with mucosal-repair peptides
- LL-37 (Cathelicidin)
- 1–5 mg (variable)
- Topical or subcutaneous (experimental)
- Antimicrobial peptide; modulates microbiome, reduces pathogenic bacterial translocation
- 7–10 days for microbiome shifts; longer for inflammation reduction
- Emerging research; potent but requires careful dosing to avoid dysbiosis
- Epithalon
- 5–10 mg (cycled)
- Subcutaneous injection
- Telomerase activation, cellular senescence reduction (indirect gut effect via systemic anti-aging)
- 30+ days (systemic effects, not gut-specific)
- Limited direct gut research; included for completeness in anti-aging protocols